Are Peptides Legal in the US? A Plain-Language Overview

Most research peptides, BPC-157, TB-500, GHK-Cu and similar compounds, are not controlled substances under federal law. Holding them and selling them for laboratory research purposes is generally lawful. What is not lawful is selling them as drugs, dietary supplements, or anything intended for human consumption without FDA approval.

That is the structure of the entire market in two sentences: lawful as research chemicals, unlawful as unapproved drugs. The line does not run through the molecule. It runs through what the molecule is sold for.

Under the Federal Food, Drug, and Cosmetic Act, a "drug" is defined partly by intended use. An article intended to diagnose, cure, mitigate, treat or prevent disease, or intended to affect the structure or function of the body, is a drug in the statutory sense whatever its chemistry. Introducing an unapproved new drug into interstate commerce is prohibited, and so is misbranding.

Intended use is established by evidence, and marketing is the primary evidence. Dosing tables, protocol suggestions, before-and-after imagery, testimonials describing personal results and outcome language in product copy all speak to intended use. This is why "research use only" is not a magic phrase that neutralizes a sale: it is a description of which side of the line a sale sits on, and it can be contradicted by everything else on the page.

A second point specific to the US market: most research peptides also fail to qualify as dietary supplements under DSHEA, because a substance investigated as a new drug before being marketed as a supplement is generally excluded from the definition. Selling them as supplements is a distinct problem from selling them as drugs, and the FDA has said so in warning letters across this category.

The Controlled Substances Act is a separate regime covering scheduled substances, and most research peptides are not scheduled under it. That is worth stating plainly because "controlled substance" is often used loosely to mean "regulated", and the two are different things: a compound can be entirely unscheduled and still be unlawful to sell for human use under the FD&C Act.

Some compound classes sold alongside peptides do have different statuses, so each compound is worth checking individually rather than by category. Anabolic agents in particular sit under their own schedule and are not comparable to peptides on this point.

• ·Buying research peptides from a US supplier for laboratory research is an ordinary transaction. No prescription exists or applies, because these are not approved drugs.
• ·Nothing sold as a research chemical is quality-assured for human use, manufactured under GMP, or dosed for any human protocol. The legal line and the safety line are the same line.
• ·A few peptide molecules also exist as approved drugs. Branded semaglutide and tirzepatide products are the obvious examples. Those approvals attach to those products through the pharmacy channel and do not extend to research-market vials of the same molecule.
• ·Compounded preparations are a third category again, made by licensed pharmacists under Sections 503A and 503B for identified patients. That channel has nothing to do with research-chemical retail, which is the point most commentary on the July 2026 vote missed.
• ·Athletes should note that many research peptides, growth hormone secretagogues among them, appear on the World Anti-Doping Agency and US Anti-Doping Agency prohibited lists. That is a separate system from federal law with its own consequences in tested sport.

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides, BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, for inclusion on the Section 503A Bulk Drug Substances List, against the recommendation of FDA staff.[1][2] Emideltide, the seventh substance under review, was not recommended. The margins were narrow: 8 to 6 with one abstention for BPC-157, KPV and TB-500, and 7 to 5 with two abstentions for MOTS-c.

That was widely reported as a change in the legal landscape. It is worth being precise about what it does:

• ·It is non-binding. The committee advises, it does not decide. No final FDA determination has been issued and none of the six peptides appears in 21 CFR 216.23.
• ·It requires a further step. Addition to the 503A Bulks List requires formal action by the Secretary of Health and Human Services, which had not occurred as of publication.
• ·It does not make the compound an FDA-approved drug, and it establishes nothing about efficacy.
• ·It does not legitimize research-chemical retail. A compounding-list decision concerns licensed pharmacists preparing patient-specific prescriptions under Section 503A, which is a different channel entirely from research material sold in vials.

Importing research compounds adds a customs layer that domestic purchase does not have. Shipments can be inspected, detained under import alert, or refused entry, and the importer carries that exposure rather than the overseas seller. FDA import alerts covering unapproved new drugs are the usual mechanism, and they operate on the shipment rather than on the buyer's intent.

Buying from US-held stock shipped domestically removes the import question entirely. That is a more substantial reason to prefer a domestic supplier than delivery speed is.

A supplier's legal posture is readable directly off its website: research-use framing throughout, no dosing instructions, no human-outcome claims, no before-and-after imagery, published third-party certificates, and clear terms of sale.

This is worth caring about for a self-interested reason as well as a principled one. FDA action against a supplier that markets to human use takes that supplier's catalog offline, and its customers' supply with it. The full due-diligence list is at how to choose a peptide supplier in the US.